Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Primary completion
- Nov 22, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07005713A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg...BeOne Medicines · Chronic Spontaneous UrticariaRecruitingONCLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04617522Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentGilead Sciences · Advanced or Metastatic Solid TumorRecruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT04999384First in Human, Dose Escalation Study of AN4005Adlai Nortye Biopharma Co., Ltd. · Advanced Solid TumorRecruitingANLLead
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT05302037Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)CytoMed Therapeutics Pte Ltd · CancerRecruitingGDTCLead
- Enrollment
- Locked
- Primary completion
- Nov 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05608681A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Eupraxia Pharmaceuticals Inc. · Eosinophilic EsophagitisRecruitingEPRXLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06049082A Study of KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyKrystal Biotech, Inc. · Alpha 1-Antitrypsin DeficiencyRecruitingKRYSLead
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06182969A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.Ascentage Pharma Group Inc. · SLERecruitingAAPGLead
- Enrollment
- Locked
- Primary completion
- Apr 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06658535A Dose Escalation Study of NanO2 in Patients With Mild Respiratory DistressNuvOx LLC · Mild Respiratory DistressRecruitingNUOXLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07219030A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult ParticipantsAbbVie · Healthy VolunteerRecruitingABBVLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07429006SAD and MAD Study of AKB-9090 in Healthy Adult ParticipantsAkebia Therapeutics · Healthy VolunteersRecruitingAKBALead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07463196A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and...AC Immune SA · Healthy ParticipantsRecruitingACIULead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07662057A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy ParticipantsArcus Biosciences, Inc. · Healthy VolunteersRecruitingRCUSLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07673601A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participantsargenx · Healthy Volunteers (HV)RecruitingARGXLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07728487Study of AT-587 in Healthy SubjectsAtea Pharmaceuticals, Inc. · Hepatitis ERecruitingAVIRLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07803744A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityEli Lilly and Company · Diabetes Mellitus, Type 1RecruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07843693A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersAbbVie · Healthy VolunteersRecruitingABBVLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07867327A Study of LY4515100 in Healthy Male ParticipantsEli Lilly and Company · HealthyRecruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07946575A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in...Trevi Therapeutics · Healthy ParticipantsRecruitingTRVILead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07777133A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy...Bristol-Myers Squibb · Healthy Female ParticipantsRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 5, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07290283A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy ParticipantsAstraZeneca · Healthy ParticipantsRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07465653A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionNovartis Pharmaceuticals · Heart Failure With Reduced Ejection FractionRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07721402A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy AdultsPfizer · Healthy ParticipantRecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07049575Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaIncyte Corporation · Hidradenitis SuppurativaRecruitingINCYLead
- Enrollment
- Locked
- Primary completion
- Dec 9, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 44 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.